What are the long-term effects of taking marijuana?

Long-term marijuana use is associated with moderate to high health risks, and the scale depends on the age of onset, frequency of use, THC dose, and method of consumption. According to the 2017 report by the National Academies of Sciences, Engineering, and Medicine, there is "decisive or significant evidence" linking chronic cannabis smoking to chronic bronchitis, and meta-analyses estimate the risk of developing addiction (cannabis use disorder) at 9-30% depending on the pattern of use (Hasin, 2015). For those starting before age 18, the risk of psychosis, cognitive disorders, and persistent changes in the prefrontal cortex increases. In this article, we show what we know today about the neurological, cardiovascular, psychiatric, respiratory, and endocrine effects of chronic marijuana use, how to reduce these risks, and where to seek help in case of addiction.

What you will find in this guide. The definition of "long-term" marijuana use based on epidemiological criteria. An overview of neurological, psychiatric, cardiovascular, respiratory, endocrine, and obstetric effects. Discussion of Cannabinoid Hyperemesis Syndrome and cannabis use disorder according to DSM-5. Practical recommendations from Lower-Risk Cannabis Use Guidelines. The Polish legal context and clinically significant differences between medical and recreational marijuana. withdrawal time how long the withdrawal effects of marijuana last /czas-odstawienia-ile-trwaja-skutki-odstawienia-marihuany/

What is the short answer to the question about the long-term effects of marijuana?

The short answer is: the risks are moderate to high among chronic users, and 9-30% of them develop a diagnostic addiction (Hasin et al., 2015). The scale of harm is greatest among those starting before the age of 18, using high-potency THC strains daily, and smoking with tobacco.

However, the situation is not black and white. The report US from 2017, the broadest contemporary review classified evidence into five categories of certainty. Only some effects, e.g., chronic bronchitis, schizophrenia in at-risk groups, low birth weight of newborns from using mothers, have the status of "decisive or significant evidence." The others are rated as moderate or limited.

For the average patient, the most important message is this. Occasional, adult, controlled use of cannabis carries moderate health risks. Chronic, daily smoking for many years, particularly starting in adolescence, is associated with specific, quantifiable harms across several organ systems.

Citation capsule. The National Academies of Sciences, Engineering, and Medicine report "The Health Effects of Cannabis and Cannabinoids" (2017) summarizes over 10,000 scientific abstracts and classifies evidence into five levels. Decisive or significant evidence relates to, among others, the link with chronic bronchitis, schizophrenia in genetically susceptible individuals, and low birth weight of newborns from using mothers.

What does "long-term" marijuana use scientifically mean?

"Long-term" marijuana use in the epidemiological literature is most often defined as daily or almost daily use (20+ days a month) lasting over 12 months. This threshold comes from the criteria of the Substance Abuse and Mental Health Services Administration (SAMHSA) and is used in the largest meta-analyses, including. Hasin et al. (2015), in NESARC-III analyses.

The definition has clinical significance. A different risk profile applies to someone smoking a joint once a month, a patient vaporizing medical cannabis under a doctor's supervision, and a chronic user of high-potency concentrates. Most of the effects discussed in this article pertain to this third group.

Usage patterns that carry the highest risk

The highest health risks are associated with five characteristic usage patterns. First, daily smoking for more than a year. Second, using high-potency strains (THC above 16%) or concentrates (THC 60-90%). Third, starting use before the age of 18. Fourth, mixing marijuana with tobacco. Fifth, combining with alcohol or other psychoactive substances.

How does "medical pattern" differ from recreational?

The medical pattern involves controlled dosing, defined clinical indications, medical monitoring, and often a shorter time horizon. The recreational pattern in chronic users typically lacks dose titration, self-selection of strains, oversight, and long-term exposure. The risk profile of these two groups differs dramatically, although the active molecules are the same.

Citation capsule. SAMHSA and NIDA define "long-term cannabis use" as daily or almost daily (20+ days a month) use lasting over 12 months. This operational threshold is used in NESARC-III analyses and in most European cohort studies. It allows separating occasional recreational use from a pattern with a documented profile of health harms.

What are the long-term neurological and cognitive effects of marijuana?

Long-term marijuana use affects short-term memory, executive functions, and (in individuals starting in adolescence) enduring parameters of cognitive functioning. A meta-analysis Crean et al. (2011) showed that deficits in working memory and attention are observed as early as 6-10 hours after the last dose, and some functions return to normal after 28 days of abstinence.

The human brain develops until about the age of 25, with the prefrontal cortex, responsible for decision-making, impulse control, and planning, maturing last. Exposure to THC during this period of intense neuroplasticity can permanently modify the architecture of synaptic connections. Therefore, neurological effects in teenagers differ qualitatively from those in adults.

Short-term and working memory

Chronic marijuana use impairs the encoding and retrieval of new information. The hippocampus, a key structure for episodic memory, has a high density of CB1 receptors, which THC acts upon. In a meta-analysis Crean et al. (2011), deficits in verbal and visual memory tests were consistently observed in chronic users, with an effect size of Cohen's d ranging from 0.4 to 0.6.

The good news. In adult users, most memory deficits resolve within 4-6 weeks of abstinence. MRI shows normalization of hippocampal volume, and neuropsychological tests show a return to normal. A reset is possible, although it requires a consistent break.

Executive functions and decision-making

Executive functions include planning, inhibiting responses, cognitive flexibility, and working memory. A study Schoeler & Bhattacharya (2014) from King's College London analyzed 105 studies on the impact of cannabis on these processes. Conclusion: moderate but consistent deficits are observed in Stroop tests, Iowa Gambling Task, and Wisconsin Card Sorting Test among chronic users.

Clinically significant. These deficits may be unnoticed in daily life but become apparent in situations requiring rapid attention switching, impulse control, or risk calculation. This is important in professional work, driving, and financial decisions.

IQ and early onset of use, Dunedin study

The most prominent study on lasting cognitive effects is the Dunedin Study, published by Meier et al. in PNAS in 2012. A cohort of 1,037 individuals from New Zealand was tracked from birth to age 38. Those who started regular marijuana use before age 18 and maintained it for the next two decades had a decrease in IQ of 6-8 points, measured by the WAIS test.

The result sparked debate. A re-analysis published by Rogeberg (PNAS, 2013) suggested that socioeconomic status may have confounded the results. Subsequent cohorts (the 2016 twin study) did not confirm the effect in full scale, although they indicated moderate deficits in some tests. The conclusion for clinical practice remains conservative: starting use before age 18 is inadvisable.

A comparison of three key cohort studies (Dunedin, Christchurch, ALSPAC) shows directional convergence. In all observations, early onset of regular marijuana use correlates with poorer educational outcomes and lower cognitive parameters in adulthood. The scale of the effect varies from moderate to large, but the direction is consistent across all analyses.

Citation capsule. The Dunedin study published in PNAS by Meier et al. (2012) included a cohort of 1,037 individuals tracked from birth to age 38. Those starting regular marijuana use before age 18 with a chronic pattern had a decrease in IQ of 6-8 points. Despite later replication debate, the direction of the early start effect remains a clinical indication to avoid use in adolescence.

Does long-term smoking of marijuana increase the risk of heart attack and other cardiovascular incidents?

Yes. Long-term smoking of marijuana is associated with a significant increase in the risk of tachycardia, blood pressure instability, and, according to a meta-analysis Wolff et al. (2015), myocardial infarction in patients with existing coronary artery disease. Newer data (the "All of Us" program, 2024) indicate a 34% higher risk of heart failure among daily users.

The pathophysiological mechanism is well documented. THC stimulates CB1 receptors in the peripheral nervous system, leading to increased sympathetic tone. The effect includes an acceleration of heart rate by 20-50% within 30 minutes, changes in blood pressure, and, in smokers, an increase in carboxyhemoglobin levels.

Tachycardia and blood pressure fluctuations

THC causes a biphasic cardiovascular response. In the first minutes after inhalation, tachycardia and increased blood pressure are observed, followed by orthostatic hypotension after 30-60 minutes. In young and healthy individuals, this is clinically insignificant. In patients with coronary disease, heart failure, or undergoing antihypertensive treatment, the effect can be dangerous.

Myocardial infarction and stroke

Review Wolff et al. (2015) summarized data on the relationship between marijuana and ischemic stroke in young adults. Cases of stroke were described in European cohorts among individuals under 45, where the only known risk factor was intense cannabis use. The mechanism involves vasospasm of cerebral arteries and platelet activation.

The risk of infarction is highest in the first hour after inhalation. A classic study Mittleman et al. (Circulation, 2001) showed a 4.8-fold increase in the risk of infarction within an hour after smoking a joint, compared to periods without use. For patients with a prior infarction, this period is clinically dangerous.

Smoke, carbon monoxide, and carboxyhemoglobin

Smoke from burned marijuana, like tobacco smoke, contains carbon monoxide that binds to hemoglobin 240 times more strongly than oxygen. The increase in carboxyhemoglobin after a smoking session reduces oxygen supply to the heart muscle. This distinguishes smoked joints from vaporized flower and even more so from oral oils. The method of administration has fundamental cardiological significance.

Citation capsule. The meta-analysis by Wolff et al. (Stroke, 2015) and earlier work by Mittleman et al. (Circulation, 2001) documented a 4.8-fold increase in the risk of acute myocardial infarction in the first hour after smoking a joint. The mechanism involves THC-induced tachycardia, increased blood pressure, platelet activation, and increased carboxyhemoglobin in smokers.

How does long-term marijuana use affect mental health, psychosis, and depression?

Daily use of high-potency THC increases the risk of psychosis and schizophrenia, particularly in individuals with a genetic predisposition. A meta-analysis Marconi et al. (2016), encompassing 10 studies and 66,816 individuals, showed an odds ratio of 3.90 for the heaviest users compared to non-users. Young adults also show an increased risk of depression and suicidal thoughts (Gobbi et al., JAMA Psychiatry, 2019).

The relationship between marijuana and mental disorders is not straightforward. There are three mechanistic hypotheses. The first is that cannabis triggers psychosis in genetically vulnerable individuals. The second is that individuals with prodromal symptoms turn to cannabis as self-medication. The third is that there is a common genetic or environmental factor. Most contemporary data supports the first hypothesis with elements of the third.

Psychosis and schizophrenia, meta-analysis Marconi 2016

Meta-analysis Marconi et al. (Schizophrenia Bulletin, 2016) is one of the most cited sources in this field. The authors summarized data from 10 cohort studies and demonstrated a dose-response relationship. The odds ratio for developing psychosis was 1.97 for occasional users and 3.90 for the most frequent users. The dose-response relationship strengthens the argument for a causal link.

Genetic predisposition COMT and AKT1

Not everyone is equally sensitive to the psychogenic effects of THC. The Val/Val variant of the COMT gene (encoding the enzyme catechol-O-methyltransferase) and the AKT1 gene polymorphism increase the risk of psychosis in marijuana users. A classic study Caspi et al. (Biological Psychiatry, 2005) showed that carriers of the Val/Val variant using cannabis in adolescence had a tenfold higher risk of psychosis by age 26.

Depression, anxiety, and suicidal thoughts in young users

The work Gobbi et al. (JAMA Psychiatry, 2019) is the broadest meta-analysis of the effects of marijuana use in adolescence on mental health in young adulthood. It included 11 studies and 23,317 individuals. The odds ratio for developing depression was 1.37, for suicidal thoughts 1.50, and for attempted suicides 3.46. Although the absolute risks remain low, the direction of the effect is clear.

Observations from the clinical practice of Polish addiction psychiatrists indicate that young patients turning to high-potency THC strains for self-medication of anxiety symptoms often experience paradoxical worsening of their condition after several months of use. This observation is also repeated in the European literature.

CBD and social phobia or can CBD oils help /cbd-i-fobia-spoleczna-czy-oleje-cbd-moga-pomoc-pozbyc-sie-leku/

Citation capsule. The meta-analysis by Marconi et al. (Schizophrenia Bulletin, 2016) on a sample of 66,816 individuals shows a dose-response relationship between marijuana use and the risk of psychosis: an odds ratio of 1.97 for occasional users and 3.90 for the most frequent users. The work by Gobbi et al. (JAMA Psychiatry, 2019) adds the anxiety and depressive picture in young adults with a 1.37-fold increase in the risk of depression.

What is cannabis use disorder and how to recognize addiction?

Cannabis use disorder (CUD) is an official diagnosis in the DSM-5 classification of the American Psychiatric Association. According to a study Hasin et al. (JAMA Psychiatry, 2015) based on a sample of 36,309 individuals, the lifetime prevalence of CUD in the USA is 6.3%, and the annual prevalence is 2.5%. Among marijuana users, 9-30% develop a full-blown picture of CUD depending on the pattern and intensity of use.

DSM-5 diagnostic criteria

The diagnosis of CUD requires meeting 2 of 11 criteria in the past 12 months. These include, among others, using larger amounts than intended, failure to cut down, significant time spent obtaining and using, substance craving, neglecting roles, continuing use despite social harms, reducing important activities, using in dangerous situations, tolerance, and withdrawal symptoms.

Severity is diagnosed in three degrees. Mild CUD (2-3 criteria), moderate (4-5), and severe (6 or more). The severity scale has clinical significance for determining the intensity of therapy.

Withdrawal symptoms of marijuana

Cannabis withdrawal syndrome was introduced to the DSM-5 as a separate entity in 2013. Symptoms include irritability, anxiety, sleep disturbances, decreased appetite, dysphoria, abdominal pain, tremors, and sweating. They appear 1-3 days after cessation, peak on days 4-7, and resolve within 1-3 weeks. Although they are milder than opioid withdrawal symptoms, they can significantly disrupt functioning and lead to relapse.

Who is most at risk for developing CUD?

Risk factors for developing CUD include: starting before age 18 (risk 4-7 times higher), daily frequency of use, using high-potency strains, male gender, co-occurring mental disorders, and a positive family history of addiction. These factors act additively, and the presence of several of them significantly increases individual risk.

Citation capsule. The study by Hasin et al. (JAMA Psychiatry, 2015) on a sample of 36,309 adult Americans (NESARC-III) showed a lifetime prevalence of cannabis use disorder at 6.3% and a 12-month prevalence at 2.5%. Among regular marijuana users, 9-30% develop CUD according to DSM-5 criteria. The highest risk pertains to those starting use in adolescence.

What is Cannabinoid Hyperemesis Syndrome and when to suspect this diagnosis?

Cannabinoid Hyperemesis Syndrome (CHS) is a paradoxical syndrome of chronic nausea, vomiting, and abdominal pain occurring in chronic marijuana users, resolving after cessation of use. The first descriptions come from Allen et al. (Gut, 2004) from Australia. The frequency of diagnosis is increasing alongside the legalization of cannabis in many countries.

Three phases of the disease

The classic description by Allen et al. distinguishes three phases. The prodromal phase lasts months to years and includes morning nausea, abdominal discomfort, and anxiety about vomiting. The hyperemetic phase consists of acute, recurrent episodes of uncontrollable vomiting, sometimes 20-30 times a day. The recovery phase follows after complete cessation of marijuana and lasts several weeks to months.

Pathognomonic symptom, hot baths

A characteristic feature of CHS, described by 90% of patients, is symptomatic relief after long hot baths or showers. Patients spend hours in the bathtub, which temporarily reduces nausea. The mechanism is linked to the activation of TRPV1 receptors by heat, which competitively modulate the action of endocannabinoids in the intestines. This symptom is so characteristic that it alone suggests a diagnosis.

Differential diagnosis and treatment

CHS is often confused with cyclic vomiting syndrome, acute gastroenteritis, mechanical obstruction, or porphyria. Diagnosis is based on exclusion and response to cessation of cannabis use. Treatment of the acute phase includes intravenous hydration, antiemetic medications, and topical application of capsaicin. Definitive treatment is abstinence.

Citation capsule. The first descriptions of Cannabinoid Hyperemesis Syndrome come from Allen et al. (Gut, 2004) from Australia. The syndrome includes three phases: prodromal (months to years), hyperemetic (recurrent vomiting 20-30 times a day), and recovery after complete abstinence. A pathognomonic symptom is relief after long hot baths, described by 90% of patients.

Does long-term smoking of marijuana cause lung cancer and bronchitis?

Long-term smoking of marijuana is associated with a documented increase in the risk of chronic bronchitis, but evidence linking it to lung cancer is limited and ambiguous. A classic paper Tashkin (Annals of the American Thoracic Society, 2013) summarized 30 years of research and showed that smoking cannabis causes typical symptoms of bronchitis (cough, phlegm, wheezing) but does not cause COPD or lasting obstructive changes in spirometry.

Chronic bronchitis

Marijuana smoke contains many of the same carcinogens as tobacco smoke: polycyclic aromatic hydrocarbons, phenols, aromatic amines. It irritates the respiratory epithelium, leading to hyperproduction of mucus, cough, and increased susceptibility to infections. These symptoms resolve in 80% of cases after one year of abstinence, as shown in the work Pletcher et al. (JAMA, 2012).

Why does marijuana not show a strong association with lung cancer?

Despite the presence of carcinogens, epidemiological cohorts do not clearly confirm the link between marijuana and lung cancer, unlike tobacco. Among the hypotheses: exposure is lower (cannabis smokers consume significantly fewer "joints" daily), there is a potential anti-cancer effect of some cannabinoids, and THC may modulate the apoptosis of precursor cells. The work Tashkin (2013) summarizes that the evidence remains insufficient.

Vaporization and edibles, a milder alternative?

Vaporizing flower reduces exposure to pyrolysis products by about 90% compared to smoking (NASEM, 2017). It also eliminates carbon monoxide, a key carcinogen. Edibles (edible forms) completely bypass the respiratory tract but introduce other risks: delayed onset of action, difficulty in dosing, risk of overdose.

what are the ways to consume marijuana overview /jakie-sa-sposoby-zazywania-marihuany-przeglad/

Citation capsule. The work by Tashkin (Annals of the American Thoracic Society, 2013) summarizes 30 years of research and shows that smoking marijuana causes chronic bronchitis but not COPD or a clear link to lung cancer. Pletcher et al. (JAMA, 2012) in a sample of 5,115 individuals tracked for 20 years found no deterioration in spirometry among cannabis smokers after adjusting for tobacco.

How does long-term marijuana use affect hormones, fertility, and semen?

Long-term marijuana use may modulate the hypothalamic-pituitary-gonadal (HPG) axis, leading to changes in testosterone levels and semen quality. The work Gundersen et al. (American Journal of Epidemiology, 2015) on a sample of 1,215 Danish men showed a 28% lower sperm concentration among those using marijuana more than once a week compared to non-users.

Impact on testosterone and the HPG axis

Endocannabinoids physiologically regulate GnRH secretion in the hypothalamus, modulating the hormonal cascade. Chronic doses of THC may lower testosterone levels by 5-15% in men, although the data remain ambiguous. Some studies show no significant changes, while others show a dose-dependent effect. The mechanism involves inhibition of pulsatile LH secretion by the pituitary.

Semen parameters, Gundersen study 2015

The work Gundersen et al. (2015) is the most cited study in this field. It included Danish men of conscription age. Using marijuana more than once a week was associated with a 28% lower sperm concentration and a 29% lower total sperm count in ejaculate. The effect was independent of the use of other psychoactive substances.

Fertility in women

In women, THC may delay ovulation, modulate the length of the menstrual cycle, and affect implantation. Data are limited, but the work Mumford et al. (Human Reproduction, 2018) showed a higher rate of anovulation among marijuana users. In the context of planning pregnancy, abstinence from both partners is recommended for 3-6 months before attempting.

Citation capsule. The work by Gundersen et al. (American Journal of Epidemiology, 2015) on a sample of 1,215 young Danes showed a 28% lower sperm concentration in men using marijuana more than once a week compared to non-users. The mechanism involves modulation of the hypothalamic-pituitary-gonadal axis and a potential impact on spermatogenesis in the testes.

What are the long-term consequences of marijuana use during pregnancy and breastfeeding?

Using marijuana during pregnancy is associated with lower birth weight, shorter duration of pregnancy, and potential long-term neurodevelopmental effects on the child. The broadest contemporary review, published by Volkow et al. in the New England Journal of Medicine (2020), summarizes the evidence and unequivocally advises against cannabis use during the prenatal and lactation periods.

Impact on birth weight and pregnancy course

Meta-analyses show that children born to women using marijuana during pregnancy are born with a lower birth weight of about 110-150 grams and have a shorter duration of pregnancy by 0.1-0.3 weeks. These effects are moderate but have documented clinical consequences for newborn development. The effect is dose-dependent and intensifies in women who smoke daily throughout pregnancy.

Long-term neurodevelopmental effects

The work Volkow et al. (NEJM, 2020) summarizes evidence for lasting neurodevelopmental effects of prenatal exposure. THC crosses the placental barrier and acts on the developing endocannabinoid system of the fetus, crucial for neuronal migration and synaptogenesis. Children exposed prenatally show slightly lower scores in attention, impulse control, and executive function tests in school-age cohort studies.

Breastfeeding

THC is a lipophilic substance, accumulating in fatty tissue and passing into breast milk. Concentrations in milk can be 8 times higher than in maternal plasma. An infant breastfed by a mother using marijuana has detectable levels of THC metabolites in urine and fatty tissue. The American Academy of Pediatrics unequivocally advises against cannabis use during lactation.

Pregnant patients often view marijuana as a "natural" way to combat morning sickness, perceiving it as safer than anti-nausea medications. This reasoning is clinically flawed. THC has a documented impact on fetal development, while anti-nausea medications (e.g., ondansetron, doxylamine) have a well-described safety profile during pregnancy.

treatment of endometriosis or can CBD help /leczenie-endometriozy-czy-cbd-moze-pomoc/

Citation capsule. The review by Volkow et al. published in the New England Journal of Medicine (2020) summarizes evidence of the harm of marijuana during pregnancy. Prenatal exposure to THC is associated with a lower birth weight of 110-150 grams, shorter duration of pregnancy, and lasting deficits in attention and executive function tests in school-age children. Breastfeeding is also contraindicated.

Does medical marijuana carry the same risks as recreational use?

Medical marijuana used under a doctor's supervision has a significantly more favorable risk-benefit profile than recreational use. The difference arises from four pillars: controlled doses, defined clinical indications, shorter time horizon, and medical monitoring. In Poland, medical marijuana is prescribed by prescription from the Rpw category, according to the amendment to the drug addiction prevention act.

Clinical context and dosage control

A patient using medical marijuana has a known content of THC and CBD (e.g., THC 19% and CBD 1% in popular Rpw strains), controls the milligram dose, keeps a symptom diary, and is periodically evaluated by a doctor. These conditions significantly reduce the risk of developing cannabis use disorder and acute psychiatric complications. The clinical pattern differs qualitatively from recreational use.

Medical indications in Poland

In clinical practice, medical marijuana in Poland is used for chronic pain (especially neuropathic), spasticity in multiple sclerosis, treatment-resistant epilepsy, anorexia in the course of cancer and HIV, and in selected sleep disorders. The Rpw prescription requires diagnostic justification and monitoring of therapy effects.

Limitations and warnings

Despite a better profile, medical marijuana is not free from risks. Young patients (under 25), with a psychotic history, pregnant, with cardiovascular diseases, and personality disorders remain in contraindicated groups. The method of administration matters. Vaporizing flower is preferred over smoking, and oral oils over both forms.

Citation capsule. Medical marijuana used under medical supervision with controlled doses and clinical indications (neuropathic pain, spasticity in MS, treatment-resistant epilepsy) has a significantly more favorable risk profile than recreational use. In Poland, it is available by prescription from the Rpw category, according to the amendment to the drug addiction prevention act. Young patients and those with a psychotic history remain in contraindicated groups.

What individual risk factors have the strongest impact on health harms?

Five factors modify the health risks associated with marijuana use the most: age of onset, genetic predispositions, frequency of use, THC dosage, and method of administration. Each of these has a documented effect in the scientific literature, and their combination results in an additive or synergistic increase in harms.

Age of onset of use

The strongest single risk factor is the age of onset. The brain matures until about the age of 25, with the prefrontal cortex maturing last. Starting use before age 18 increases the risk of developing cannabis use disorder by 4-7 times, the risk of psychosis by 2-5 times, and the risk of lasting cognitive deficits. After age 25, risks decrease, although they do not disappear.

Genetic predispositions

Polymorphisms of the COMT, AKT1, BDNF, and CNR1 genes modify individual sensitivity to the psychogenic and cognitive effects of THC. Individuals with a positive family history of schizophrenia, psychosis, or addiction have a higher risk regardless of the usage pattern. This is one of the arguments for advising against cannabis in this patient group.

Frequency, dosage, and method of use

Daily use is associated with greater risk than occasional use. High-potency strains (THC above 16%) and concentrates (THC 60-90%) carry a greater risk of psychosis and CUD than classic flower (5-12% THC). Smoking with tobacco is the worst method of administration due to additive respiratory, cardiovascular risks, and synergistic nicotine addiction risk.

A comparison of risk factors shows a clear hierarchy. The age of onset acts as a multiplier for all other factors. A teenager using high-potency concentrates daily has a qualitatively different risk profile than an adult occasional user of mild flower. This gradient should guide health education.

Citation capsule. Five factors modify the health risks of marijuana the most: age of onset, genetic predispositions (COMT, AKT1), frequency of use, THC concentration, and method of administration. Starting before age 18 increases the risk of cannabis use disorder by 4-7 times, and the risk of psychosis by 2-5 times. High-potency concentrates and smoking with tobacco represent the highest structural risk.

How to reduce health risks according to Lower-Risk Cannabis Use Guidelines?

Lower-Risk Cannabis Use Guidelines developed by Fischer et al. (American Journal of Public Health, 2017) are 10 evidence-based principles aimed at minimizing harm for individuals who have chosen to use cannabis. The guidelines are analogous to those for alcohol and are characterized by pragmatic harm reduction, not promotion of use.

Ten principles of harm reduction

1. The best method to avoid risk is abstinence, especially among youth and at-risk individuals.
2. Delay the onset of use as long as possible, ideally until the age of 25.
3. Choose products with lower THC concentrations and higher CBD (CBD modulates the effects of THC).
4. Avoid concentrates and synthetic cannabinoids (so-called "spice", "K2"), which have unpredictable effects.
5. Prefer non-smoking forms: vaporizing flower, oral oils, sublingual tinctures.
6. Avoid deep inhalations and holding smoke, which increase exposure to carcinogens.
7. Limit the frequency of use, no more than occasionally (a few times a month, not daily).
8. Do not drive or operate machinery under the influence of cannabis (the psychomotor effect lasts 4-6 hours).
9. Avoid use in high-risk groups: pregnancy, lactation, positive psychotic history, heart disease, before age 25.
10. Avoid risky combinations: use with tobacco, alcohol, or other psychoactive substances.

Polish practical context

In Poland, possession and use of marijuana is illegal (Act of July 29, 2005 on drug addiction prevention). The guidelines by Fischer et al. are informational and educational. A patient in the Polish healthcare system should distinguish illegal cannabis (THC above 0.3%) from legal CBD products (THC below 0.3%) and medical marijuana by prescription Rpw.

how long do the effects last after smoking marijuana and THC /jak-dlugo-utrzymuja-sie-efekty-po-paleniu-marihuany-i-thc-rozpracowujemy-skutki/

Citation capsule. Lower-Risk Cannabis Use Guidelines developed by Fischer et al. (American Journal of Public Health, 2017) are 10 evidence-based principles. The key recommendations are: delay the start of use until age 25, prefer low THC concentrations and high CBD, avoid concentrates, non-smoking forms (vaporization, oral oils), and limit frequency to occasional.

Where to seek help in Poland in case of marijuana addiction?

In case of suspected cannabis use disorder, effective help includes psychiatric consultation, psychotherapy (CBT, motivational interviewing), and, in severe cases, inpatient treatment. In Poland, a wide network of addiction therapy centers from the MONAR Association and NFZ centers provide free or low-cost therapeutic help.

The most effective therapeutic approaches

Cognitive Behavioral Therapy (CBT) and motivational interviewing (MI) have the most evidence of effectiveness in treating cannabis use disorder. Meta-analyses show that 10-12 sessions of structured CBT or MI reduce use by 30-50% over a period of 6-12 months. Contingency management (motivational system) increases effectiveness when used additionally.

Polish MONAR centers and the NFZ system

The MONAR Association operates over 35 inpatient centers and dozens of outpatient clinics in Poland. The centers accept patients for free, long-term (6-18 months) therapy programs. The NFZ also finances addiction treatment clinics (PZP), 24-hour therapeutic units, and outpatient treatment. The first contact does not require a referral.

Crisis hotline

Free helplines: Child and Youth Trust Line 116 111 (24/7), Anti-Drug Trust Line 800 199 990 (daily 16-21), Adult Emotional Crisis Line 116 123. In case of immediate life-threatening situations (suicidal thoughts, psychosis, poisoning), the emergency number is 112.

withdrawal time how long the withdrawal effects of marijuana last /czas-odstawienia-ile-trwaja-skutki-odstawienia-marihuany/

Citation capsule. In treating cannabis use disorder, Cognitive Behavioral Therapy and motivational interviewing are the most effective. Meta-analyses show a reduction in use by 30-50% over a period of 6-12 months after 10-12 sessions. In Poland, the MONAR network and addiction treatment clinics funded by the NFZ provide free, comprehensive care without the need for a referral.

What is the current legal status of marijuana in Poland?

In Poland, possession, cultivation, and trade of marijuana containing THC above 0.3% remain illegal under the Act of July 29, 2005 on drug addiction prevention. The exception is medical marijuana available by prescription Rpw and hemp products with THC content below 0.3% (e.g., CBD oils), which are fully legal.

What does the drug addiction prevention act regulate?

The Act of July 29, 2005 defines marijuana as a narcotic substance from groups I-N and IV-N. Possession is punishable by imprisonment for up to 3 years (up to 10 years for significant amounts). Article 62a introduced the possibility of conditional discontinuation in cases of possessing a small amount for personal use if the penalty would be disproportionate to the gravity of the act. The decision is up to the prosecutor.

Medical marijuana, prescription Rpw

Since 2017, medical marijuana has been legally available in Poland by prescription from the Rpw category, issued by a specialist doctor or the attending physician. Import is handled by pharmaceutical wholesalers, and the patient fills the prescription at a pharmacy (usually at a pharmacy indicated by the wholesaler). The price per gram is 50-80 PLN and is not reimbursed by the NFZ.

CBD products and legal status

Oils, flowers, and CBD supplements with THC content below 0.3% are fully legal in Poland, according to EU law. The legal classification includes dietary supplements and cosmetics. The novel food status for oral CBD products is under regulation at the European Commission level. A report WHO ECDD from 2018 confirmed the good safety profile of CBD.

Citation capsule. The Act of July 29, 2005 on drug addiction prevention classifies marijuana with THC above 0.3% as a narcotic substance. Possession is punishable by up to 3 years of imprisonment (Article 62), with the possibility of conditional discontinuation (Article 62a). Medical marijuana has been legal since 2017 by prescription Rpw, and CBD oils with THC below 0.3% are fully legal as dietary supplements.

FAQ: frequently asked questions about the long-term effects of marijuana

Does long-term smoking of marijuana definitely damage memory?

Yes, but in a moderate and partially reversible way. The meta-analysis by Crean et al. (2011) shows deficits in working memory and attention in chronic users with an effect size of Cohen's d ranging from 0.4 to 0.6. In adults, most deficits resolve after 4-6 weeks of abstinence. In individuals starting before age 18, changes may be more lasting.

What is the real risk of psychosis after chronic marijuana use?

Among daily users of high-potency THC, the risk of psychosis increases by up to five times according to the meta-analysis by Marconi et al. (2016). The odds ratio is 3.90 for the most frequent users. The risk is dramatically higher in carriers of the Val/Val variant of the COMT gene and individuals with a positive family history of schizophrenia. The absolute risk remains low in healthy adults.

Does marijuana really cause addiction?

Yes, although the addictive potential is lower than that of alcohol, opioids, or nicotine. According to the study by Hasin et al. (JAMA Psychiatry, 2015), 9-30% of regular users develop cannabis use disorder according to DSM-5. The risk is highest (up to 30-50%) among those starting before age 18 and using high-potency strains daily.

Does smoking marijuana cause lung cancer?

The evidence is limited and ambiguous. The work by Tashkin (Annals of the American Thoracic Society, 2013) summarizes 30 years of research and does not confirm a strong link, unlike tobacco. Smoking marijuana causes chronic bronchitis, cough, and phlegm, but not COPD or a clear increase in lung cancer risk. Most symptoms resolve within a year of abstinence.

How long do withdrawal symptoms of marijuana last?

Cannabis withdrawal syndrome according to DSM-5 includes irritability, anxiety, sleep disturbances, decreased appetite, dysphoria, abdominal pain. Symptoms appear 1-3 days after cessation, peak on days 4-7, and resolve within 1-3 weeks. Although they are milder than those of opioids, they can significantly hinder functioning and lead to relapse.

Does CBD carry the same risks as THC?

No. CBD has a fundamentally different pharmacological and safety profile. The WHO ECDD report (2018) confirms that CBD does not cause addiction, does not induce tachycardia or vasospasm characteristic of THC, and has no psychoactive effects. The main risks of CBD are drug interactions (CYP3A4, CYP2C9), drowsiness, and gastrointestinal disturbances at high doses.

Is marijuana dangerous during pregnancy?

Yes. The review by Volkow et al. (NEJM, 2020) summarizes the evidence of harm. Prenatal exposure to THC is associated with a lower birth weight of 110-150 grams, shorter duration of pregnancy, and lasting deficits in attention and executive function tests in school-age children. Breastfeeding is also contraindicated (THC accumulates in breast milk).

Is medical marijuana safer than recreational?

Yes, but the difference arises from context, not chemistry. Medical marijuana used under a doctor's supervision, with controlled dosing and defined indications, has a more favorable risk-benefit profile. The THC molecule, however, acts pharmacologically the same regardless of the source. Young patients, pregnant individuals, and those with a psychotic history remain in contraindicated groups for medical marijuana as well.

Where to seek help in case of marijuana addiction in Poland?

In Poland, free help for cannabis use disorder is available through the network of MONAR centers (over 35 inpatient centers, dozens of outpatient clinics) and addiction treatment clinics funded by the NFZ. The first contact does not require a referral. Additionally, free helplines are available: 116 111 (youth), 800 199 990 (addictions), 112 (critical situations).

When is the drop in IQ after marijuana real, and when is it a myth?

A drop in IQ is documented in individuals starting regular use before age 18 and maintaining a chronic pattern. The Dunedin study (Meier 2012) showed a drop of 6-8 IQ points by age 38 in this group. In adults starting after age 18, lasting IQ deficits are not demonstrated. Most cognitive function deficits in adults are reversible after abstinence.

Summary: what to remember about the long-term effects of marijuana?

Long-term use of marijuana carries moderate to high health risks, the scale of which depends on the age of onset, frequency of use, THC dosage, and method of consumption. The most strongly documented harms are chronic bronchitis, cannabis use disorder (9-30% of regular users), increased risk of psychosis in genetically vulnerable individuals, and negative impacts on the developing adolescent brain.

The most vulnerable groups are those starting use before age 18, pregnant and breastfeeding women, patients with a psychotic history, cardiovascular diseases, and a positive family history of schizophrenia. For these populations, marijuana remains a relative or absolute contraindication, both in recreational and medical versions.

Most cognitive deficits and symptoms resolve after a full abstinence lasting 4-6 weeks. Cannabis use disorder is effectively treated through Cognitive Behavioral Therapy, motivational interviewing, and, in more severe cases, in inpatient programs (including MONAR centers in Poland). The first contact with the help system does not require a referral or additional formalities.

Finally, in the Polish legal system, possession of marijuana remains illegal (Act of July 29, 2005), except for medical marijuana by prescription Rpw and CBD products with THC below 0.3%. A conscious distinction between these categories is practically significant for the patient and their attending physician.

what we should know about marijuana /co-powinnismy-wiedziec-o-marihuanie/

Medical disclaimer. This article is educational and does not constitute medical advice. It does not replace consultation with a psychiatrist, addiction therapy specialist, or family doctor. In case of problems with marijuana use or suspicion of cannabis use disorder, consult a psychiatrist or addiction specialist. In case of psychotic symptoms, suicidal thoughts, or life-threatening situations, immediately call emergency number 112. In Poland, possession of marijuana containing THC above 0.3% remains illegal under the Act of July 29, 2005 on drug addiction prevention. Medical marijuana is available only by prescription from the Rpw category, issued by a doctor. CBD products with THC content below 0.3% are fully legal as dietary supplements. Do not discontinue any prescribed medications without consulting your attending physician. CBD products are not medications, do not diagnose, treat, or prevent diseases. During pregnancy, breastfeeding, and in individuals under 18, cannabis products are contraindicated.

Author. Michał Waluk, the substantive editor of the blog ubucha.pl, specializes in cannabis, cannabinoids, and the pharmacology of medical marijuana. The texts are developed based on peer-reviewed scientific literature (tier 1-3, including NEJM, JAMA Psychiatry, Schizophrenia Bulletin, American Journal of Public Health, Stroke, PNAS) and official positions of scientific societies (NASEM, WHO, EMA, NIDA, SAMHSA).